Remifentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats via inducible nitric oxide synthase expression

Anesthesiology

Volumn 114, Issue 5, 2011, Pages 1036-1047

  Yang, Li Qun ^a   Tao, Kun Ming ^a   Liu, Yan Tao ^a   Cheung, Chi Wai ^b   Irwin, Michael G ^a   Wong, Gordon T C ^b   Lv, Hao ^a   Song, Jian Gang ^a   Wu, Fei Xiang ^a   Yu, Wei Feng ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ARGININE; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; MYELOPEROXIDASE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REMIFENTANIL; SUPEROXIDE DISMUTASE;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATION; ISCHEMIC PRECONDITIONING; LIPID PEROXIDATION; LIVER INJURY; LIVER ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 79955466532     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182104956     Document Type: Article

References (45)

1. Ogura Y, Takagi K, Kawarada Y, Mizumoto R: Pathophysiological effect of hepatic ischemia and reperfusion after hepatectomy in dogs with obstructive jaundice, focusing on the effect of coenzyme Q10 and styrene-co-maleic acid superoxide dismutase. J Gastroenterol 1996; 31:379-86.
2. Serracino-Inglott F, Habib NA, Mathie RT: Hepatic ischemiareperfusion injury. Am J Surg 2001; 181:160-6.
3. Walsh KB, Toledo AH, Rivera-Chavez FA, Lopez-Neblina F, Toledo-Pereyra LH: Inflammatory mediators of liver ischemia-reperfusion injury. Exp Clin Transplant 2009; 7:78-93.
4. Zhang W, Wang M, Xie HY, Zhou L, Meng XQ, Shi J, Zheng S: Role of reactive oxygen species in mediating hepatic ischemia-reperfusion injury and its therapeutic applications in liver transplantation. Transplant Proc 2007; 39:1332-7. (Pubitemid 46915523)
5. Wong GT, Li R, Jiang LL, Irwin MG: Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand 2010; 54:510-8.
6. Kato R, Foëx P: Myocardial protection by anesthetic agents against ischemia-reperfusion injury: An update for anesthesiologists. Can J Anaesth 2002; 49:777-91. (Pubitemid 35469040)
7. Charron C, Messier C, Plamondon H: Neuroprotection and functional recovery conferred by administration of kappaand delta 1-opioid agonists in a rat model of global ischemia. Physiol Behav 2008; 93:502-11. (Pubitemid 351208432)
8. Zongze Z, Jia Z, Chang C, Kai C, Yanlin W: Protective effects of remifentanil on septic mice. Mol Biol Rep 2010; 37: 2803-8.
9. Wong GT, Huang Z, Ji S, Irwin MG: Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: A randomized trial. J Cardiothorac Vasc Anesth 2010; 24:790-6.
10. Wittert G, Hope P, Pyle D: Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 1996; 218:877-81. (Pubitemid 26050757)
11. Kim JS, Lemasters JJ: Opioid receptor-independent protection of ischemic rat hepatocytes by morphine. Biochem Biophys Res Commun 2006; 351:958-64. (Pubitemid 44715878)
12. Domínguez FE, Siemers F, Flohé S, Nau M, Schade FU: Effects of endotoxin tolerance on liver function after hepatic ischemia/ reperfusion injury in the rat. Crit Care Med 2002; 30:165-70. (Pubitemid 34112192)
13. Inglott FS, Mathie RT: Nitric oxide and hepatic ischemiareperfusion injury. Hepatogastroenterology 2000; 47:1722-5.
14. Li C, Jackson RM: Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002; 282:C227-41. (Pubitemid 34663181)
15. Terui K, Enosawa S, Haga S, Zhang HQ, Kuroda H, Kouchi K, Matsunaga T, Yoshida H, Engelhardt JF, Irani K, Ohnuma N, Ozaki M: Stat3 confers resistance against hypoxia/reoxygenation-induced oxidative injury in hepatocytes through upregulation of Mn-SOD. J Hepatol 2004; 41:957-65. (Pubitemid 39575663)
16. Warltier DC, Pagel PS, Kersten JR: Approaches to the prevention of perioperative myocardial ischemia. ANESTHESIOLOGY 2000; 92: 253-9. (Pubitemid 30027471)
17. Zhang Y, Irwin MG, Wong TM: Remifentanil preconditioning protects against ischemic injury in the intact rat heart. ANESTHESIOLOGY 2004; 101:918-23. (Pubitemid 39288042)
18. Servin FS, Billard V: Remifentanil and other opioids. Handb Exp Pharmacol 2008:283-311.
19. Yu CK, Li YH, Wong GT, Wong TM, Irwin MG: Remifentanil preconditioning confers delayed cardioprotection in the rat. Br J Anaesth 2007; 99:632-8. (Pubitemid 351773220)
20. Yamanouchi K, Yanaga K, Okudaira S, Eguchi S, Furui J, Kanematsu T: [D-Ala2, D-Leu5] enkephalin (DADLE) protects liver against ischemia-reperfusion injury in the rat. J Surg Res 2003; 114:72-7. (Pubitemid 37108678)
21. Watkins LR, Hutchinson MR, Rice KC, Maier SF: The "toll" of opioid-induced glial activation: Improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009; 30:581-91.
22. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR: Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24:83-95.
23. Bonnet MP, Beloeil H, Benhamou D, Mazoit JX, Asehnoune K: The mu opioid receptor mediates morphine-induced tumor necrosis factor and interleukin-6 inhibition in toll-like receptor 2-stimulated monocytes. Anesth Analg 2008; 106: 1142-9. (Pubitemid 351450539)
24. Shen XD, Ke B, Zhai Y, Gao F, Busuttil RW, Cheng G, Kupiec-Weglinski JW: Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant 2005; 5:1793-800. (Pubitemid 41039851)
25. Zhang Y, Wu YX, Hao YB, Dun Y, Yang SP: Role of endogenous opioid peptides in protection of ischemic preconditioning in rat small intestine. Life Sci 2001; 68:1013-9. (Pubitemid 32168053)
26. Khiabani KT, Kerrigan CL: Presence and activity of nitric oxide synthase isoforms in ischemia-reperfusion-injured flaps. Plast Reconstr Surg 2002; 109:1638-45. (Pubitemid 34273372)
27. Abe Y, Hines I, Zibari G, Grisham MB: Hepatocellular protection by nitric oxide or nitrite in ischemia and reperfusion injury. Arch Biochem Biophys 2009; 484:232-7.
28. Chattopadhyay P, Verma N, Verma A, Kamboj T, Khan NA, Wahi AK: L-arginine protects from pringle manoeuvere of ischemia-reperfusion induced liver injury. Biol Pharm Bull 2008; 31:890-2. (Pubitemid 351731984)
29. Chen T, Zamora R, Zuckerbraun B, Billiar TR: Role of nitric oxide in liver injury. Curr Mol Med 2003; 3:519-26. (Pubitemid 37168596)
30. Elrod JW, Duranski MR, Langston W, Greer JJ, Tao L, Dugas TR, Kevil CG, Champion HC, Lefer DJ: eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: A role for eNOS uncoupling. Circ Res 2006; 99:78-85. (Pubitemid 44297058)
31. Kaizu T, Ikeda A, Nakao A, Takahashi Y, Tsung A, Kohmoto J, Toyokawa H, Shao L, Bucher BT, Tomiyama K, Nalesnik MA, Murase N, Geller DA: Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival. Hepatology 2006; 43:464-73.
32. Hsu CM, Wang JS, Liu CH, Chen LW: Kupffer cells protect liver from ischemia-reperfusion injury by an inducible nitric oxide synthase-dependent mechanism. Shock 2002; 17:280-5.
33. Wang Y, Lawson JA, Jaeschke H: Differential effect of 2-aminoethyl-isothiourea, an inhibitor of the inducible nitric oxide synthase, on microvascular blood flow and organ injury in models of hepatic ischemia-reperfusion and endotoxemia. Shock 1998; 10:20-5. (Pubitemid 128463258)
34. Koti RS, Tsui J, Lobos E, Yang W, Seifalian AM, Davidson BR: Nitric oxide synthase distribution and expression with ischemic preconditioning of the rat liver. FASEB J 2005; 19: 1155-7. (Pubitemid 40946449)
35. Lee VG, Johnson ML, Baust J, Laubach VE, Watkins SC, Billiar TR: The roles of iNOS in liver ischemia-reperfusion injury. Shock 2001; 16:355-60. (Pubitemid 33598210)
36. Wang CC, Cheng PY, Peng YJ, Wu ES, Wei HP, Yen MH: Naltrexone protects against lipopolysaccharide/D-galactosamine-induced hepatitis in mice. J Pharmacol Sci 2008; 108:239-47.
37. Terra SG, Tsunoda SM: Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann Pharmacother 1998; 32:1228-30. (Pubitemid 28543471)
38. Jaume M, Jacquet S, Cavaillès P, Macé G, Stephan L, Blanpied C, Demur C, Brousset P, Dietrich G: Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology 2004; 40:1136-43. (Pubitemid 39425569)
39. Payabvash S, Kiumehr S, Nezami BG, Zandieh A, Anvari P, Tavangar SM, Dehpour AR: Endogenous opioids modulate hepatocyte apoptosis in a rat model of chronic cholestasis: The role of oxidative stress. Liver Int 2007; 27:538-47. (Pubitemid 46534576)
40. Payabvash S, Beheshtian A, Salmasi AH, Kiumehr S, Ghahremani MH, Tavangar SM, Sabzevari O, Dehpour AR: Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. Life Sci 2006; 79:972-80. (Pubitemid 44061875)
41. Su TP: Delta opioid peptide[D-Ala(2),D-Leu(5)]enkephalin promotes cell survival. J Biomed Sci 2000; 7:195-9.
42. Chakass D, Philippe D, Erdual E, Dharancy S, Malapel M, Dubuquoy C, Thuru X, Gay J, Gaveriaux-Ruff C, Dubus P, Mathurin P, Kieffer BL, Desreumaux P, Chamaillard M: micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut 2007; 56:974-81. (Pubitemid 46999084)
43. Davis M: Cholestasis and endogenous opioids: Liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007; 46:825-50. (Pubitemid 47443308)
44. Liu L, Zhu J, Glass PS, Brink PR, Rampil IJ, Rebecchi MJ: Age-associated changes in cardiac gene expression after preconditioning. ANESTHESIOLOGY 2009; 111:1052-64.
45. Amour J, Brzezinska AK, Jager Z, Sullivan C, Weihrauch D, Du J, Vladic N, Shi Y, Warltier DC, Pratt PF Jr, Kersten JR: Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin-and heat shock protein 90-mediated mechanisms. ANESTHESIOLOGY 2010; 112:576-85